Table 3.
Cannabis substitution for pharmaceuticals among 275 Michigan medical cannabis patients, influences for substitution, and primary care provider knowledge of substitution
| Influences for substitution (%) | |||||||
|---|---|---|---|---|---|---|---|
| Substance type | Use n (%) | Substitution (%) | Experiences | Healthcare provider | Dispensary | Individuals | Other |
| Amphetamines | 52 (19%) | 75 | 89 | 11 | 0 | 3 | 14 |
| Anticonvulsants | 30 (13%) | 70 | 87 | 22 | 4 | 8 | 4 |
| Antidepressants | 141 (51%) | 53 | 93 | 22 | 7 | 6 | 6 |
| Antiemetics | 33, 12% | 79 | 87 | 13 | 4 | 0 | 4 |
| Antihistamines | 94, 34% | 36 | 100 | 3 | 0 | 3 | 6 |
| Antipsychotics | 19 (7%) | 78 | 71 | 43 | 0 | 7 | 0 |
| Anxiolytics or benzodiazepines | 64 (23%) | 73 | 87 | 34 | 4 | 8 | 8 |
| Muscle relaxers | 107 (39%) | 82 | 88 | 15 | 3 | 5 | 11 |
| Non-opioid pain relievers | 93 (34%) | 76 | 97 | 10 | 4 | 6 | 12 |
| Nonsteroidal anti-inflammatories | 125 (46%) | 62 | 92 | 14 | 3 | 4 | 9 |
| Opioids | 102 (37%) | 86 | 88 | 28 | 11 | 9 | 12 |
| Non-amphetamine stimulants | 19 (7%) | 50 | 89 | 11 | 0 | 11 | 22 |
| Prescription cannabinoids | 5 (2%) | 75 | 75 | 0 | 0 | 25 | 25 |
| Sedatives | 34 (12%) | 88 | 93 | 25 | 7 | 4 | 14 |
| Sleep aids | 79 (29%) | 83 | 95 | 15 | 6 | 8 | 5 |
| Steroids | 44 (16%) | 64 | 55 | 18 | 2 | 0 | 2 |
N = 275 participants total, 192 of whom reported any substitution. Note: all values are proportions of relevant groups. Use indicates proportion of participants who have used a substance. Substitution indicates proportion of participants using a substance who have reduced or stopped their use because of medical cannabis. Influences for substitution include participant’s own experimentation and experiences, advice from primary health/medical care provider, advice from my medical marijuana caregiver/dispensary, advice from other individual(s), and other source of information
PCP primary care provider